Literature DB >> 870426

Antibody to Corynebacterium parvum in normal human and animal sera.

G Wolberg, G S Duncan, C Adlam, J K Whisnant.   

Abstract

Using a microtiter bacterial agglutination test, we have estimated antibodies to Corynebacterium parvum in "normal" human and "normal" and immune animal sera. Widely differing levels of C. parvum antibodies were found in the normal human sera. The median titer for all 310 human sera was 1:128, whereas that for the 1- to 17-year and 18- to 50-year subgroups was 1:64 and 1:512, respectively. Antibody titers in the various animal species were generally much lower.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870426      PMCID: PMC421475          DOI: 10.1128/iai.15.3.1004-1007.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Bacteriological survey of anaerobic Corynebacterium in human bone marrow and blood.

Authors:  T Hattori; A Mori
Journal:  Gan       Date:  1973-02

2.  Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice.

Authors:  M F Woodruff; W H McBride; N Dunbar
Journal:  Clin Exp Immunol       Date:  1974-07       Impact factor: 4.330

3.  Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies.

Authors:  J B Robbins; J C Parke; R Schneerson; J K Whisnant
Journal:  Pediatr Res       Date:  1973-03       Impact factor: 3.756

4.  Quantitation of Corynebacterium acnes on healthy human skin.

Authors:  D A Somerville; C T Murphy
Journal:  J Invest Dermatol       Date:  1973-04       Impact factor: 8.551

5.  Corynebacterium parvum: a synonym for Propionibacterium acnes?

Authors:  C S Cummins; J L Johnson
Journal:  J Gen Microbiol       Date:  1974-02

6.  Diphtheroid infections of man.

Authors:  K Kaplan; L Weinstein
Journal:  Ann Intern Med       Date:  1969-05       Impact factor: 25.391

7.  Biological purpose of acne.

Authors:  S Shuster
Journal:  Lancet       Date:  1976-06-19       Impact factor: 79.321

Review 8.  Corynebacterium parvum as an immunotherapeutic anticancer agent.

Authors:  M T Scott
Journal:  Semin Oncol       Date:  1974-12       Impact factor: 4.929

9.  Incidence and lipolytic activity of Propionibacterium acnes (Corynebacterium acnes group I) and P. granulosum (C. acnes group II) in acne and in normal skin.

Authors:  J A Whiteside; J G Voss
Journal:  J Invest Dermatol       Date:  1973-02       Impact factor: 8.551

10.  The effect of Corynebacterium parvum therapy on immunoglobulin class and IgG subclass levels in cancer patients.

Authors:  K James; G J Clunie; M F Woodruff; W H McBride; W H Stimson; R Drew; D Catty
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640

View more
  6 in total

1.  Interferon production and lymphocyte stimulation in human leucocyte cultures stimulated by Corynebacterium parvum.

Authors:  H M Hirt; M Schwenteck; H Becker; H Kirchner
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

2.  Experimental intraocular malignancy: the effect of intracameral perfusion.

Authors:  V G Wong; W R Green; Y P Liu; E R Marsden
Journal:  Trans Am Ophthalmol Soc       Date:  1979

3.  Biotyping of Propionibacterium acnes isolated from normal human facial skin.

Authors:  M Kishishita; T Ushijima; Y Ozaki; Y Ito
Journal:  Appl Environ Microbiol       Date:  1979-10       Impact factor: 4.792

4.  Immune reaction of tumor-bearing mice to Propionibacterium acnes and the antitumor effect of the bacteria.

Authors:  V Silobrcic; G Fredrickson; R Sedlacek; H D Suit; G Wolberg
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Immune response modulation by colonization of germfree rats with Propionibacterium acnes.

Authors:  C L Wells; E Balish
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

6.  Chemotactic efficiency of various chemoattractants for polymorphonuclear leukocytes in inflammatory acne vulgaris.

Authors:  J Knop; T Bossecker; P M Kövary
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.